Goodwin advised Sage Therapeutics on the transaction Sage Therapeutics (NASDAQ:SAGE) executed the pricing of an underwritten public offering of 3,506,098 shares of its common stock at…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now